Company: OSRH
Filing Date: 2025-08-29
Form Type: DEF 14A
Source: 0001213900-25-082061
Chunk: 3

Company: OSR Holdings, Inc.
Filing Date: 2025-08-29
Form: DEF 14A
Chunk 3
---
 STOCKHOLDERS TO BE HELD ON SEPTEMBER 17, 2025 This proxy statement, along with the accompanying Notice of Annual Meeting, contains information about the annual meeting of stockholders (the “Annual Meeting”) of OSR Holdings, Inc. (f/k/a Bellevue Life Sciences Acquisition Corp.), including any adjournments or postponements thereof. We are holding the Annual Meeting at 9 a.m. Eastern time on September 17, 2025, at the office of the Company’s legal counsel, Drohan Lee LLP, located at 5 Penn Plaza, 19 thFloor, New York, NY 10001. In this proxy statement, we refer to OSR Holdings, Inc. as “the Company,” “we” and “us.” This proxy statement relates to the solicitation of proxies by our Board of Directors (the “Board”) for use at the Annual Meeting to be held on September 17, 2025, is dated and will be distributed or made available, as the case may be, to our stockholders on or about August 29, 2025. IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING The Annual Meeting will be conducted for the sole purpose of considering and voting upon the following proposals: 1. Proposal 1 — Director Proposal:A proposal to elect seven directors to the Company’s Board of Directors (the “Board”), each to serve until the next annual meeting of stockholders following this Annual Meeting or until each such director’s successor is elected and qualified, subject to his earlier death, resignation or removal (the “Director Proposal” or Proposal No. 1). 2. Proposal 2 — Executive Compensation Proposal:A proposal to approve, on a non -bindingadvisory basis, the compensation of the Company’s named executive officers (the “Executive Compensation Proposal” or Proposal No. 2). 3. Proposal 3 — Equity Plan Proposal:A proposal to approve compensation terms and adopt share -basedincentive sub -planspursuant to the Company’s 2025 Omnibus Incentive Plan (“Omnibus Plan”) (the “Equity Plan Proposal” or Proposal No. 3). 4. Proposal 4 — Proposal to Exceed 20% Common Share Issuance Pursuant to Nasdaq Listing Rule 5635(d):To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance by the Company of shares of its common stock (and/or securities convertible into or exercisable for